Citadel Advisors’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,592,429
| Closed | -$115M | – | 14045 |
|
|
2025
Q4 | $115M | Buy |
1,592,429
+692,665
| +77% | +$44.7M | 0.02% | 771 |
|
|
2025
Q3 | $39.2M | Buy |
899,764
+878,042
| +4,042% | +$35.5M | 0.01% | 1623 |
|
|
2025
Q2 | $617K | Buy |
21,722
+5,540
| +34% | +$165K | ﹤0.01% | 8139 |
|
|
2025
Q1 | $478K | Sell |
16,182
-395,493
| -96% | -$12.3M | ﹤0.01% | 8576 |
|
|
2024
Q4 | $12M | Buy |
+411,675
| New | +$17.2M | ﹤0.01% | 2751 |
|
|
2024
Q3 | – | Sell |
-160,777
| Closed | -$6.98M | – | 15083 |
|
|
2024
Q2 | $6.57M | Buy |
160,777
+57,644
| +56% | +$1.65M | ﹤0.01% | 3350 |
|
|
2024
Q1 | $2.63M | Sell |
103,133
-390,529
| -79% | -$6.12M | ﹤0.01% | 5007 |
|
|
2023
Q4 | $4.47M | Buy |
493,662
+263,314
| +114% | +$1.76M | ﹤0.01% | 3961 |
|
|
2023
Q3 | $1.47M | Sell |
230,348
-122,899
| -35% | -$1.06M | ﹤0.01% | 5808 |
|
|
2023
Q2 | $3.92M | Buy |
353,247
+248,225
| +236% | +$3.11M | ﹤0.01% | 4025 |
|
|
2023
Q1 | $1.61M | Buy |
105,022
+97,398
| +1,278% | +$2.14M | ﹤0.01% | 5773 |
|
|
2022
Q4 | $169K | Sell |
7,624
-48,777
| -86% | -$727K | ﹤0.01% | 10416 |
|
|
2022
Q3 | $921K | Buy |
56,401
+17,338
| +44% | +$332K | ﹤0.01% | 7179 |
|
|
2022
Q2 | $568K | Buy |
39,063
+19,965
| +105% | +$297K | ﹤0.01% | 8360 |
|
|
2022
Q1 | $353K | Buy |
+19,098
| New | +$324K | ﹤0.01% | 10208 |
|
|
2020
Q3 | – | Sell |
-273,220
| Closed | -$7.72M | – | 10633 |
|
|
2020
Q2 | $7.72M | Buy |
+273,220
| New | +$7.88M | ﹤0.01% | 2531 |
|
Other funds holding RNAM
Citadel Advisors's RNAM Position: Q1 2026 in Review
Citadel Advisors sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 1,592,429 shares — an estimated $115M sold.
Citadel Advisors first reported a position in RNAM in Q2 2020 and held it in 16 quarters. The position peaked at $115M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Citadel Advisors reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 1,592,429 Avidity Biosciences shares in Q1 2026, an estimated $115M.
- Citadel Advisors first reported a position in Avidity Biosciences in Q2 2020 and held it in 16 quarters.
- Citadel Advisors's Avidity Biosciences position peaked at $115M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.